Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

New Assay Technology and Utility of Peripheral Blood Vs Bone Marrow for Molecular MRD in AML and MDS

Magnus Tobiasson, Linus Bosaeus, Lucia Cavelier, Lei Chen

Blood (2023) 142 (Supplement 1): 6039.

https://doi.org/10.1182/blood-2023-183013

Published: 2023

Journal Articles

Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma

Dai Chihara, Laura Liao, Joseph Tkacz, Anjali Franco, Benjamin Lewing, Karl M. Kilgore, Loretta J. Nastoupil, Lei Chen

Blood (2023) 142 (12): 1047–1055.

https://doi.org/10.1182/blood.2023020197

Published: 2023

Includes: Supplemental data

Journal Articles

SETD2 Regulates Nuclear Division to Achieve Polyploidization in Megakaryocyte

Lei Chen, Jingkun Liu, Kunying Chen, Yanxun Su, Ying Lei, Jia Si, Jie Zhang, Zhaojun Zhang, Weiguo Zou, Xiaohui Zhang, Matthew T. Rondina, Qian-Fei Wang, Qian-fei Wang

Blood (2022) 140 (Supplement 1): 5730–5731.

https://doi.org/10.1182/blood-2022-157981

Published: 2022

Journal Articles

Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy

Mehdi Hamadani, Laura Liao, Lauren Wilson, Amanda Howarth, Carlos Flores, Lei Chen

Blood (2022) 140 (Supplement 1): 8058–8060.

https://doi.org/10.1182/blood-2022-167753

Published: 2022

Journal Articles

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US

Dai Chihara, Laura Liao, Joseph Tkacz, Benjamin Lewing, Anjali Franco, Karl M. Kilgore, Loretta J. Nastoupil, Lei Chen

Blood (2022) 140 (Supplement 1): 2421–2423.

https://doi.org/10.1182/blood-2022-163678

Published: 2022

Journal Articles

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Jipan Xie, MD PhD, Aozhou Wu, PhD, Laura Liao, MS, Xiaoyan Du, MESc, Ahmed Noman, BA, Yawen Liang, PhD, Joseph Camardo, MD, Lei Chen, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140136

Published: 2020

Journal Articles

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Alexander I. Spira, PhD MD FACP, Lei Chen, MD PhD, Xiaolei Zhou, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael Curiel, John A. Radford, MD FMedSci, Brad S. Kahl, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139571

Published: 2020

Journal Articles

Fto Promotes Extramedullary Progression of Multiple Myeloma By Regulation of HSF1 through m 6 a RNA Methylation

Aoshuang Xu, MD, Jiasi Zhang, MD, Liping Zuo, MD, Jian Xu, PhD, Xuejiao Yin, MD, Qianwen Cheng, MD, Yuyang Zhang, MD, Lei Chen, PhD, Fei Zhao, PhD, Fengjuan Fan, PhD, Yu Hu, Chunyan Sun, MD PhD

Blood (2019) 134 (Supplement_1): 3063.

https://doi.org/10.1182/blood-2019-125635

Published: 2019

Journal Articles

Myelofibrosis osteoclasts are clonal and functionally impaired

Ivo Veletic, Taghi Manshouri, Asha S. Multani, C. Cameron Yin, Lei Chen, Srdan Verstovsek, Zeev Estrov

Blood (2019) 133 (21): 2320–2324.

https://doi.org/10.1182/blood-2018-10-878926

Published: 2019

Includes: Supplemental data

Journal Articles

Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis

Taghi Manshouri, PhD, Ivo Veletic, MD, C. Cameron Yin, MD PhD, Lei Chen, MD, Joseph E. Bove, IV, Ying Zhang, MDMS, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2018) 132 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2018-99-119064

Published: 2018

Journal Articles

Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation

Yueying Li, Chen Jin, Hao Bai, Yongxing Gao, Shu Sun, Lei Chen, Lei Qin, Paul P. Liu, Linzhao Cheng, Qian-Fei Wang

Blood (2018) 131 (2): 191–201.

https://doi.org/10.1182/blood-2017-04-780379

Published: 2018

Includes: Supplemental data

Journal Articles

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Nanxin Li, Chelsey Yang, Liangyi Fan, Todor Totev, Annie Guerin, MSc, Lei Chen, MDPhD

Blood (2015) 126 (23): 2090.

https://doi.org/10.1182/blood.V126.23.2090.2090

Published: 2015

Journal Articles

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Richard T. Maziarz, MD, Annie Guerin, MSc, Genevieve Gauthier, MSc, Julie Heroux, MSc, Maryia Zhdanava, MSc, Eric Q Wu, PhD, Simu K Thomas, PhD, Lei Chen, MDPhD

Blood (2015) 126 (23): 872.

https://doi.org/10.1182/blood.V126.23.872.872

Published: 2015

Journal Articles

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Lei Chen, MD PhD, Dominick Latremouille-Viau, MSc, Annie Guerin, MSc, Roy Nitulescu, MSc, Patrick Gagnon-Sanschagrin, BSc

Blood (2015) 126 (23): 1596.

https://doi.org/10.1182/blood.V126.23.1596.1596

Published: 2015

Journal Articles

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

B. Douglas Smith, MD, Jun Liu, PhD, Dominick Latremouille-Viau, MSc, Zhou Zhou, MSc, Annie Guerin, MSc, Daniel Fernandez, MA, Dingdong Yi, BS, Xufei Wang, MA, Eric Q Wu, PhD, Shivani K Mhatre, MSc, Christopher H Keir, MD, Lei Chen, MD PhD

Blood (2014) 124 (21): 2618.

https://doi.org/10.1182/blood.V124.21.2618.2618

Published: 2014

Journal Articles

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Blood (2014) 124 (21): 1293.

https://doi.org/10.1182/blood.V124.21.1293.1293

Published: 2014

Journal Articles

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Annie Guerin, MSc, Cindy Revol, MPH, Agnihotram V. Ramanakumar, PhD, Rebekah Foster, BA, Eric Qiong Wu, PhD, Shivani K Mhatre, MSc, Lei Chen, MD PhD

Blood (2014) 124 (21): 1304.

https://doi.org/10.1182/blood.V124.21.1304.1304

Published: 2014

Journal Articles

Treatment and Management of Chronic Myelogenous Leukemia in Patients Cared for in a Large HMO

Reina Haque, PhD MPH, Jiaxiao Shi, PhD, Joanie Chung, MPH, Chantal C Avila, MA, Lei Chen, MD PhD, Joanne E Schottinger, MD

Blood (2014) 124 (21): 1310.

https://doi.org/10.1182/blood.V124.21.1310.1310

Published: 2014

Journal Articles

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Lei Chen, MD, PhD, Annie Guerin, MSc, Maryna Marynchenko, MBA, Raluca Ionescu-Ittu, PhD, Robert Hiscock, MSc, Roy Nitulescu, MA, Chopra Pooja, MSc, Ling-I Hsu, MPH, Christopher Keir, MD, Eric Qiong Wu, PhD

Blood (2013) 122 (21): 4038.

https://doi.org/10.1182/blood.V122.21.4038.4038

Published: 2013

Journal Articles

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Daniel J. DeAngelo, MD, PhD, Lei Chen, MD, PhD, Annie Guerin, MSc, Amy Styles, MSc, Clemence Aberki, BSc, Philippe Giguere-Duval, BSc, Eric Qiong Wu, PhD

Blood (2012) 120 (21): 2792.

https://doi.org/10.1182/blood.V120.21.2792.2792

Published: 2012

NARROW

New Assay Technology and Utility of Peripheral Blood Vs Bone Marrow for Molecular MRD in AML and MDS

Real-world experience of CAR T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma

SETD2 Regulates Nuclear Division to Achieve Polyploidization in Megakaryocyte

Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy

Real-World Effectiveness and Economic Impact Associated with Chimeric Antigen Receptor T-Cell Therapy Among Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in US

Characteristics and Treatment Patterns of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Received ≥3 Lines of Therapies

Symptoms, Health-Related Quality of Life, and Tolerability of Loncastuximab Tesirine in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma

Fto Promotes Extramedullary Progression of Multiple Myeloma By Regulation of HSF1 through m 6 a RNA Methylation

Myelofibrosis osteoclasts are clonal and functionally impaired

Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis

Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation

Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data

Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective

Treatment Patterns and Healthcare Costs in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As First-Line Therapy in the United States: A Retrospective Claims Database Analysis

Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy

A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib As Second-Line Therapy after Imatinib

Twelve-Month Cost per Responder (CPR) Analysis of Nilotinib and Dasatinib As Front-Line Therapy in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Treatment and Management of Chronic Myelogenous Leukemia in Patients Cared for in a Large HMO

Impact Of Low-Grade Adverse Events (AEs) On Health-Related Quality Of Life (HRQoL) In Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia In Chronic Phase (Ph+ CML-CP) From The Enestnd Trial: 48-Month Follow-Up

Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only